High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
62.48M
+11.88%
0.566
+8.76%
60.75M
+10.81%
0.538
+9.75%
62.38M
+11.95%
0.570
+16.33%
Estimates Revision
The market is revising Upward the revenue expectations for LeMaitre Vascular, Inc. (LMAT) for FY2025, with the revenue forecasts being adjusted by 2.6% over the past three months. During the same period, the stock price has changed by 8.15%.
Revenue Estimates for FY2025
Revise Upward
+2.6%
In Past 3 Month
EPS Estimates for FY2025
No Change
0.00%
In Past 3 Month
Stock Price
Go Up
+8.15%
In Past 3 Month
8 Analyst Rating
0Wall Street analysts forecast LMAT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LMAT is 108.60 USD with a low forecast of 92.00 USD and a high forecast of 120.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
4 Hold
0 Sell
Moderate Buy
0Current: 84.240
Low
92.00
Averages
108.60
High
120.00
0Current: 84.240
Low
92.00
Averages
108.60
High
120.00
Barrington Research
Michael Petusky
Buy
to
Hold
Downgrades
n/a
2025-02-28
Reason
Barrington Research
Michael Petusky
Price Target
n/a
2025-02-28
Downgrades
Buy
to
Hold
Reason
Citizens Capital Markets
Daniel Stauder
Strong Buy
Maintains
$105 → $110
2025-02-28
Reason
Citizens Capital Markets
Daniel Stauder
Price Target
$105 → $110
2025-02-28
Maintains
Strong Buy
Reason
Lake Street
Brooks O'Neil
Strong Buy
Maintains
$105 → $110
2025-02-28
Reason
Lake Street
Brooks O'Neil
Price Target
$105 → $110
2025-02-28
Maintains
Strong Buy
Reason
Wells Fargo
Nathan Treybeck
Hold
Initiates
$95
2025-02-13
Reason
Wells Fargo
Nathan Treybeck
Price Target
$95
2025-02-13
Initiates
Hold
Reason
Wells Fargo analyst Nathan Treybeck initiated coverage of LeMaitre with an Equal Weight rating and $95 price target. The firm believes the company's high-single-digit pricing contribution to 2025 organic growth is already priced into the stock. LeMaitre is a leading player in several niche open vascular surgery markets, but the shares offer limited upside from current levels, the analyst tells investors in a research note. Wells says a key debate in the stock is how long the recent price floor adjustments can sustain above-historical pricing growth.
Barrington Research
Michael Petusky
Buy
Maintains
$92 → $93
2024-11-01
Reason
Barrington Research
Michael Petusky
Price Target
$92 → $93
2024-11-01
Maintains
Buy
Reason
Oppenheimer
Suraj Kalia
Buy
Reiterates
$90 → $93
2024-11-01
Reason
Oppenheimer
Suraj Kalia
Price Target
$90 → $93
2024-11-01
Reiterates
Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for LeMaitre Vascular Inc (LMAT.O) is 36.94, compared to its 5-year average forward P/E of 39.77. For a more detailed relative valuation and DCF analysis to assess LeMaitre Vascular Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
Fair
5Y Average PE
39.77
Current PE
36.94
Overvalued PE
45.26
Undervalued PE
34.28
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
Fair
5Y Average EV/EBITDA
23.69
Current EV/EBITDA
24.40
Overvalued EV/EBITDA
27.39
Undervalued EV/EBITDA
20.00
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
Fair
5Y Average PS
6.74
Current PS
7.60
Overvalued PS
8.03
Undervalued PS
5.45
Financials
Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC
Trading Trends
Insider
Insiders areSelling! The selling amount has increased 989.36% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areSelling! The selling amount has increased 398.42% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areSelling! The selling amount has increased 989.36% over the last month.
Sold
Bought
LMAT News & Events
Events Timeline
(ET)
2025-05-01
17:01:38
LeMaitre cuts FY25 EPS view to $2.07-$2.24 from $2.15-$2.32, consensus $2.23
2025-05-01
16:59:29
LeMaitre sees Q2 EPS 55c-59c, consensus 58c
2025-05-01
16:58:29
LeMaitre reports Q1 EPS 48c, consensus 50c
Sign Up For More Events
Sign Up For More Events
News
Preview
4.0
06-12NASDAQ.COMPeek Under The Hood: SDVY Has 12% Upside
Preview
5.0
06-09GlobenewswireAnteris Appoints David Roberts and Gregory Moss to its Board of Directors
Preview
8.0
05-13NASDAQ.COMEx-Dividend Reminder: Select Medical Holdings, LeMaitre Vascular and Selective Insurance Group
Sign Up For More News
People Also Watch
FAQ
What is LeMaitre Vascular Inc (LMAT) stock price today?
What is LeMaitre Vascular Inc (LMAT)'s business?
What is the price predicton of LMAT Stock?
What is LeMaitre Vascular Inc (LMAT)'s revenue for the last quarter?
What is LeMaitre Vascular Inc (LMAT)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for LeMaitre Vascular Inc (LMAT)'s fundamentals?
How many employees does LeMaitre Vascular Inc (LMAT). have?